Brief: Ns Pharma, European Commission Granted Orphan Drug Designation To Ns-229 For Treatment Of Eosinophilic Granulomatosis With Polyangiitis
22/01/2024 14:19
Jan 22 (Reuters) - Nippon Shinyaku Co Ltd 4516.T :
* NS PHARMA, INC. : EUROPEAN COMMISSION (EC) GRANTED ORPHAN
DRUG
DESIGNATION TO NS-229 FOR TREATMENT OF EOSINOPHILIC
GRANULOMATOSIS WITH POLYANGIITIS
* NS PHARMA, INC. : ORPHAN DRUG DESIGNATION TO NS- 229
PROVIDES NS
PHARMA WITH A TEN-YEAR MARKETING EXCLUSIVITY PERIOD
Source text for Eikon: ID:nPn7tsB70a
Further company coverage: 4516.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)